Dogwood Therapeutics Files 8-K: Board & Compensation Updates

Ticker: DWTX · Form: 8-K · Filed: Jun 24, 2025 · CIK: 1818844

Dogwood Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyDogwood Therapeutics, INC. (DWTX)
Form Type8-K
Filed DateJun 24, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: governance, executive-compensation, board-changes

Related Tickers: DWTX

TL;DR

Dogwood Therapeutics (DWTX) filed an 8-K detailing board changes and executive comp. Watch for governance shifts.

AI Summary

Dogwood Therapeutics, Inc. announced on June 18, 2025, a change in its board of directors and executive compensation arrangements. The company also filed financial statements and exhibits related to these matters. This filing follows the company's name change from Virios Therapeutics, Inc. in December 2020.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Filings related to board and executive changes can introduce uncertainty about leadership direction and strategic focus.

Key Players & Entities

FAQ

What specific changes were made to the board of directors?

The filing indicates a departure of directors and the election of new directors, but the specific names and details of these changes are not provided in the provided text.

What are the details of the new compensatory arrangements for certain officers?

The filing mentions compensatory arrangements of certain officers, but the specific details of these arrangements are not included in the provided text.

What matters were submitted to a vote of security holders?

The filing indicates that matters were submitted to a vote of security holders, but the specific nature of these matters is not detailed in the provided text.

When did Dogwood Therapeutics, Inc. officially change its name?

Dogwood Therapeutics, Inc. officially changed its name from Virios Therapeutics, Inc. on December 17, 2020.

What is the primary business of Dogwood Therapeutics, Inc. according to its SIC code?

According to its Standard Industrial Classification (SIC) code 2834, Dogwood Therapeutics, Inc. is primarily involved in Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 24, 2025 regarding Dogwood Therapeutics, Inc. (DWTX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing